India, Nov. 9 -- Amended: Added stock quote.
PharmAla Biotech Holdings Inc. (MDXXF), a biotechnology company focused on developing and manufacturing MDXX-class compounds, including MDMA, announced Monday that it has signed a supply and data agreement with Aalborg University Hospital in Denmark for a clinical trial evaluating MDMA-assisted treatment for service-related post-traumatic stress disorder (PTSD).
Under the agreement, PharmAla will be the sole supplier of its proprietary LaNeo MDMA for the MIRROR study, titled "A Randomized, Open-label, Rater-Blinded, Controlled Trial of Psychotherapy versus Music-Assisted Relaxation in MDMA-Facilitated Treatment for Service-Related PTSD."
The study, sponsored by Aalborg University Hospital, wil...